Sign in
CompletedPhase 3

Opioid Analgesic Reduction Study

Key facts

Who runs it
Rutgers, The State University of New Jersey
Where
Ann Arbor, Baltimore, Chicago, Newark, and Rochester, United StatesSee the 5 sites
Trial code
Status
Completed
Phase
Phase 3
People taking part
1,815 people enrolled
Started
4 Jan 2021
Ended
24 Dec 2023
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • opioid-containing analgesic
  • two over-the-counter analgesics
Record updated
31 August 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 26 criteriaShow less

Who can take part

  • An individual must meet all of the following criteria to be eligible to participate in the study:
  • Be able to understand the informed consent
  • Provide signed and dated informed consent form
  • Be able to understand all directions for data gathering instruments in English
  • Be willing and able to comply with all study procedures and be available for the duration of the study
  • Planning to undergo extraction of one or more partial or fully impacted mandibular 3rd molars
  • Be 18 years or older
  • Be in good general health as evidenced by medical history
  • Women must agree to use one of the following methods of contraception while participating in this study:; contraceptive pill; intra-uterine device; condoms; abstinence

Who cannot take part

  • Any prior respiratory effect of an opioid or other anesthetic drugs that required respiratory support postoperatively
  • Currently taking any of the following medications:; CYP3A4 inhibitor, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), which may increase plasma concentrations of hydrocodone bitartrate and acetaminophen and prolong opioid adverse reactions, and which may cause potentially fatal respiratory depression; CNS depressants
  • Prior participation in this study
  • History of gastrointestinal bleeding and/or peptic ulcer
  • History of renal disease (excluding kidney stones)
  • History of hepatic disease
  • History of bleeding disorder
  • History of respiratory depression
  • History of known allegoric reaction to ibuprofen, acetaminophen, hydrocodone, and/or anesthesia
  • Consumes 3 or more alcoholic drinks every day and/or has a history of alcoholism
  • History of drug or alcohol abuse
  • Family history of drug or alcohol abuse in a first-degree relative
  • Participants who self-report the following history will be excluded from participating:
  • Active or untreated asthma
  • Has had no more than one opioid prescription filled within the past 12 months
  • Currently pregnant or lactating; Participants would also be excluded due to any additional criteria that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study which includes:
  • Inability or refusal to provide informed consent

Where in United States

  • University of MichiganAnn Arbor, United States
  • University of MarylandBaltimore, United States
  • University of Illinois at ChicagoChicago, United States
  • Rutgers School of Dental MedicineNewark, United States
  • University of RochesterRochester, United States

About the trial

What the trial wants to find out

The goal is to provide health care professionals, including dentists, with the best possible evidence for clinical decision making when deciding upon analgesics for acute post-surgical pain management, a double-blind, stratified randomized clinical trial will be conducted to test the hypothesis that a combination of over-the-counter non-opioid containing analgesics is at least as, if not more, effective (non-inferior) than the most commonly prescribed opioid analgesic. The impacted 3rd molar extraction model will be used due to the predictable severity of the post-operative pain and generalizability of results.

Read full original descriptionShow less

This double-blind, prospective, stratified, randomized pragmatic clinical trial will use the impacted 3rd molar extraction pain model.

The 2 groups in the trial

  • OpioidExisting treatment, for comparison

    Combination analgesic of hydrocodone 5mg/acetaminophen 300 mg and a placebo pill.

    Treatment: opioid-containing analgesic

  • Non-OpioidExisting treatment, for comparison

    Combination of ibuprofen 400 mg/acetaminophen 500 mg

    Treatment: two over-the-counter analgesics

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Opioid Analgesic Reduction Study (OARS): Managing Acute Post-Operative Surgical Pain
Record updated
31 August 2026